Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F M Smith

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Toxicology and Applied Pharmacology|August 26, 1998
The reproductive toxicity of molinate and metabolites to the male rat: effects on testosterone and sperm morphologyM K Ellis, A G Richardson, J R Foster, et al.
The Journal of Biological Chemistry|June 27, 1997
Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptorM Lackmann, R J Mann, L Kravets, et al.
The Annals of Thoracic Surgery|July 13, 2000
The heart reinnervates after transplantationD A Murphy, G W Thompson, J L Ardell, et al.
Leukemia|December 7, 2016
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemiaS Charmsaz, F Al-Ejeh, T M Yeadon, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Toxicology and Applied Pharmacology|August 26, 1998
The reproductive toxicity of molinate and metabolites to the male rat: effects on testosterone and sperm morphologyM K Ellis, A G Richardson, J R Foster, et al.
The Journal of Biological Chemistry|June 27, 1997
Ligand for EPH-related kinase (LERK) 7 is the preferred high affinity ligand for the HEK receptorM Lackmann, R J Mann, L Kravets, et al.
The Annals of Thoracic Surgery|July 13, 2000
The heart reinnervates after transplantationD A Murphy, G W Thompson, J L Ardell, et al.
Leukemia|December 7, 2016
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemiaS Charmsaz, F Al-Ejeh, T M Yeadon, et al.
Pageof 9